cri-one
Contents
100%
Your journey

Health Recovery - Seven Integrated Health Research Projects (33-health-recovery)

Inventory item: 8481 | SKU: 2062 | Line: Blueprints

Page: https://cri-one.com/33-health-recovery.html

Owner and author: Christopher Gabriel Brown (CRI-ONE)

Record date: 8 October 2026

Approved public wording item: medical and regulatory wording follows D:/special/_inventory/descriptions-public/8481.md.

1. The Record in Brief

Health Recovery (33-health-recovery) is the integrated health-science research bundle of Christopher Gabriel Brown (CRI-ONE): the OTC Vitamins formulation lines, the Alchemy Probability Data analysis engine, the Diabetes, Alzheimer's and Parkinson's Research Discovery projects, the 300-Disease Mechanism Database and the NeuroElement Brain Formulation, held in one package (Evidence 1). It is a research and discovery IP record and makes no treatment claim. Its earliest dated disclosure is the 2017 deposition record: depositions #148, #201 and #373 of the 2017 catalog and deposition #769, printed on page 181 of Invent Depositions, ISBN 978-1-979767-89-7, first shipped 24 November 2017 (Evidence 3, 4, 5). Its USPTO record is five pending applications, from U.S. Application No. 19/441,975, received 7 January 2026, to the umbrella U.S. Application No. 19/693,405, filed 30 May 2026 (Evidence 6 to 10). The bundle was first listed on cri-one.com on 6 June 2026, its current item page and card Buy button went live on 8 October 2026, and the package carries the notice "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved." (Evidence 2, 14, 15).

2. Proprietary - What Is Owned and How It Is Held

The source folder D:/special/33-health-recovery/ holds 3,571 files (folder count of 8 October 2026; 16.05 GB per D:/special/33-health-recovery/_TOC.md) in eight parts:

  • OTC Vitamins (KidVital and VitalCore), 26 files: nine formulation specifications and a master ingredient database in JSON, with regulatory and packaging specifications.
  • Diabetes Research Discovery (Project 10), 26 files: discovery script and data, three known-properties report versions, a 20-claim application draft, four patent drawings, two 11 x 17 charts.
  • Alzheimer's Research Discovery (Project 11), 25 files, in the same structure.
  • Parkinson's Research Discovery (Project 12), 42 files, with the USPTO forms and the 19/445,644 receipt.
  • 300-Disease Mechanism Database (Project 13), 420 files: 61 Python scripts, the disease research documents and the 19/630,444 application papers and receipt.
  • NeuroElement Brain Formulation (Project 22), 91 files: 23 Python files of 5,998 lines, four pytest modules, the 19/555,525 application text and receipt.
  • Disease Control Revised (Project 104), assembled and indexed 6 October 2026, 2,929 files: a local retrieval index over the health folders, a pH normality ledger, a probability rebuild, a trial-evidence sweep and the Alchemy Probability Data substrate of 2,839 files (D:/special/33-health-recovery/104-disease-control-revised/README.md).
  • Bundle root and sales pitches, 12 files: README, LICENSE, MANIFEST.json, CHANGELOG, CITATION.cff, PLAYBOOK, tables of contents and the sales-pitch files.

By family: 128 Python files (32,035 lines) with PHP, JavaScript, TypeScript and batch tools; 438 Markdown and 39 text documents; 136 SVG drawings; 61 JSON, 20 CSV and one SQLite data files; 19 PDF, 4 ODF and 3 DOCX documents; 37 HTML pages; 2,614 .gz and 8 .zip archives. A second copy of 153 files under D:/special/45-fda-rebuttles-and-adwork/33-health-recovery/ carries a byte-identical LICENSE and adds the owner's FDA and FTC regulatory-positioning memo, rebuttal notes, red-team and steelman proofs and an essay.

Ownership. The LICENSE, headed "PROPRIETARY AND CONFIDENTIAL", states that the Work is "the exclusive property of Christopher Gabriel Brown." (Evidence 2). He is the filer and first named inventor on the four acknowledgement receipts of record (Evidence 6 to 9). No assignment is of record.

What a buyer receives. The LICENSE reads: "NO LICENSE IS GRANTED. No part of this Work may be copied, modified, distributed, sublicensed, sold, published, or otherwise transferred without the express written permission of the copyright holder." (Evidence 2). The item page states: "Intellectual property is not conveyed with purchase; IP-related terms require separate negotiation." (Evidence 15). The purchase term at https://cri-one.com/terms reads "When you buy, you buy the use of that blueprint only." (D:/special/crione-static/pages/terms/index.html); every Payment Link requires the buyer to agree to it before Stripe takes the payment (D:/special/crione-static/delivery-v2/README.md). The delivery file of record is 33-health-recovery__2026-09-04.zip, 11,779,106 bytes, SHA-256 beginning 37a14f97fbb1, the file the old store linked (D:/special/crione-static/delivery-v2/product_deliverables.csv).

Secrecy measures (18 U.S.C. 1839(3)). Full packages go only to paying buyers by private download link; the item page states "Your files arrive by email after payment." (Evidence 15). The mutual NDA, Version 2026-10-08, is published at https://cri-one.com/nda/ and states that every purchase on cri-one.com is made under it (D:/special/crione-static/pages/nda/index.html); its full text goes with every delivery email (D:/special/crione-static/delivery-v2/README.md). The public item page carries only the description; the code, data, drawings, reports and application papers stay inside the delivered package.

3. First Art - The Earliest Dated Disclosure

DateRecordWhat it disclosesSource
2017 (entry mark)2017 catalog, deposition #148Healthy-human chemistry balanced organ by organ, the brain includedEvidence 3, 5
2017 (entry mark)2017 catalog, deposition #201Insulin medicine through the autoimmune systemEvidence 3, 5
2017 (entry mark)2017 catalog, deposition #373Toxic and valence testing for diseases like Alzheimer'sEvidence 3, 5
24 Nov 2017Invent Depositions, ISBN 978-1-979767-89-7, #769, page 181The proper chemicals in the brain without poisoning other organsEvidence 3, 4
7 Jan 2026U.S. Application No. 19/441,975 receivedZinc-amino acid complexes, Alzheimer's lineEvidence 6
12 Jan 2026U.S. Application No. 19/445,644 receivedMetal-amino acid complexes, Parkinson's lineEvidence 7
3 Mar 2026U.S. Application No. 19/555,525 receivedNeuroElement composition and design methodEvidence 8
27 Mar 2026U.S. Application No. 19/630,444 receivedMulti-element coordination complexesEvidence 9
30 May 2026U.S. Application No. 19/693,405 filedUmbrella framework naming Project 33Evidence 10, 11

Deposition anchors (D:/Rebuttals/_registers/DEPOSITIONS_A.json, confirmed in the master IP register, Evidence 3; origin-story files in D:/manager/book-ocr-2017-invent-depositions/origin-stories/):

  • #148, anchor 2017 catalog (Evidence 5), register line 535: "can we figure out the chemistry in a healthy human, then make a ph balance inside each organ including the brain and thus making chemistry balance to help the new and exciting way of working with illness in reverse?" Its origin-story file names #148 the origin of the 300-Disease Mechanism Database.
  • #201, anchor 2017 catalog, register line 871: "immune systemic insulin. insulin medicine to magistrate through the auto immune system". Its origin-story file maps #201 to Project 10.
  • #373, anchor 2017 catalog, register line 1061: "by way of toxic and valance testing to include but not limited to cancer and diseases like alzheimer's and substance abuse cessation aids." Its origin-story file maps #373 to Project 11.
  • #769, anchor printed book page 181 (Evidence 4), register line 1500: "chemical balance relation goal is the chance to achieve the proper chemicals in the brain or an organ to make it work better and function regulatory like while not poisoning the other organs"

Each entry carries the mark "copyright © 2017 chris g brown". The master IP register D:/special/82-alchemy-calc-two/1 light trigger.txt (1,769 lines) is the source of record; the copy inside this package's Project 104 folder is byte-identical to it (SHA-256 2dcb359de3f1b56d, D:/Rebuttals/_evidence/8481.sha256).

Defensive-publication effect. Under 35 U.S.C. 102(a)(1), a printed publication or other public availability before a filing date is prior art against that filing. The 2017 depositions stand against every later filer on healthy-human chemistry balance, insulin-medicine research, element-valence testing across diseases and brain chemical balance. A challenger must produce a dated record earlier than 24 November 2017 disclosing the same research program. None is of record.

Prior Art Considered and Distinguished

The third-party art this package names sits in the NeuroElement filing papers: paragraph [0009] of the application text and the "Existing Patents to Monitor" table of the filing checklist (Evidence 12; D:/special/33-health-recovery/22-brain-chemistry/patent_application/NONPROVISIONAL_UTILITY_PATENT_APPLICATION.md).

ReferenceTitle as recordedDistinction
US 9,301,966 B2Magnesium compositions and uses thereofMg L-threonate alone for cognition; here one of seven components
US 8,734,855 B2Slow release metal amino acid chelatesGeneric "additional metal ions"; no seven-component combination or mechanism rationale
US 2022/0054537 A1Title not recordedMg L-threonate with neurotransmitter precursors; no ebselen, iron bisglycinate or NAC
US 2022/0233484 A1Title not recordedMg L-threonate with homotaurine; single disease, two components
CN 114304610 ATitle not recordedMg L-threonate with metal ions; not the seven-component combination or design method

The search list carried in the Project 104 folder is the WritePhi optical-substrate scan list (D:/special/33-health-recovery/104-disease-control-revised/google_patents_search_list.txt); its references, among them US 4,740,266, US 5,228,001, US 7,508,234 and US 8,597,871, address optical data storage, optically reconfigurable gate arrays and direct-write lithography, a field this health research bundle does not occupy.

4. First to File - The USPTO Record

U.S. ApplicationFiledStatus of recordWhat it covers for this productSource
19/441,9757 Jan 2026Pending; reply with fees and extension recorded 17 Sep 2026Alzheimer's Research DiscoveryEvidence 6
19/445,64412 Jan 2026Pending; reply with fees and extension recorded 17 Sep 2026Parkinson's Research DiscoveryEvidence 7
19/555,5253 Mar 2026Pending; Filing Receipt mailed 13 Aug 2026NeuroElement Brain FormulationEvidence 8
19/630,44427 Mar 2026Pending300-Disease line coordination complexesEvidence 9
19/693,40530 May 2026Pending; Filing Receipt mailed 25 Jun 2026Umbrella; Project 33 in its as-filed catalogEvidence 10, 11

Every application is dated by its own effective filing date. The USPTO Electronic Acknowledgement Receipts record 19/441,975 at 01/07/2026 09:50:07 AM ET (Confirmation No. [redacted]); 19/445,644 at 01/12/2026 01:28:59 AM ET (No. [redacted]); 19/555,525 at 03/03/2026 05:06:50 PM ET (No. [redacted]); and 19/630,444 at 03/27/2026 01:03:43 AM ET (No. [redacted]), titled "Novel Advanced Multi-Element Coordination Complexes for Broad-Spectrum Therapeutic Applications" (Evidence 6 to 9). The umbrella 19/693,405 carries Confirmation No. [redacted], and its as-filed catalog lists "33. OTC Vitamins for Children and Adults (Health Recovery) - Project 33" (Evidence 10, 11). The receipt copies delivered inside the Project 12, 13 and 22 folders are byte-identical to the USPTO receipts on file (D:/Rebuttals/_evidence/8481.sha256). Status follows D:/Rebuttals/_registers/USPTO_REGISTER.json and D:/USPTO Responses/_MERGE_NOTE_2026-09-17.md. The register records no benefit claim for the four subject applications, and the 19/693,405 Filing Receipt lists no domestic benefit claim; each stands on its own date. A challenger must produce an application with an effective filing date earlier than the matching application of record (7 January 2026 for the Alzheimer's line, 12 January 2026 for the Parkinson's line, 3 March 2026 for NeuroElement, 27 March 2026 for the coordination-complex library) claiming the same subject matter. None is of record.

Marking line: Patent pending - U.S. Application Nos. 19/441,975, 19/445,644, 19/555,525, 19/630,444 and 19/693,405.

5. First to Market - The Dated Public Offering

DateEventWhereSource
6 Jun 2026Listing "Integrated Health-Science IP Portfolio - Full Use & Copy License" created, onlinecri-one.com, old storeEvidence 14
31 Aug 2026Blueprint record 33-health-recovery (SKU 2062) createdcri-one.com, old storeD:/manager/_store/export_catalog_product_20260831_201548.csv
1 Sep 2026Record re-created; kept in the 7 Sep 2026 exportcri-one.com, old storeD:/manager/export_catalog_product_20260907_110415.csv
4 Sep 2026Delivery file 33-health-recovery__2026-09-04.zip datedDelivery copiesD:/special/crione-static/delivery-v2/product_deliverables.csv
8 Oct 2026, 03:55 UTCFirst new-site email campaign to US company prospects startedcri-one.com mailD:/Rebuttals/_registers/FIRST_TO_MARKET_REGISTER.json
8 Oct 2026Item page publishedcri-one.com/inventory/item-8481/Evidence 15
8 Oct 2026, 05:06 UTCStripe card Payment Link (created 04:56:07Z) public as the Buy buttonItem pageD:/special/crione-static/delivery-v2/payment_links_ledger.live.json

The 6 June 2026 listing (SKU ACQ-33-HEALTH-SCIENCE-PORTFOLIO) is the earliest of five product-line listings for this item in the 2026 catalog exports (Evidence 14; D:/Rebuttals/_registers/FIRST_TO_MARKET_REGISTER.json). Each bundled component line holds its own first-to-market record in this series (items 8447, 8452, 8456, 8457, 8458, 8459 and 8470).

6. Copyright

Notice: "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved." (package LICENSE and its byte-identical copy in the second source folder, Evidence 2). The deposition text is marked "copyright © 2017 chris g brown" entry by entry (Evidence 3, 5). The item page closes with "© 2026 Christopher Gabriel Brown (CRI-ONE), cri-one.com." (Evidence 15).

Works covered. Text (research reports, methodology statements, disease research documents, application texts), drawings (136 SVG files, among them the patent figures and 11 x 17 charts), code (128 Python files), data compilations (formulation specifications, discovery data, databases), pictures (the MetalloDrugDB product image) and web pages (37 HTML files). Copyright protects this expression; the compositions and methods are held by the patent filings and by confidentiality (17 U.S.C. 102(b)).

Registrations. The owner's written corpus is anchored by 20 registrations marked verified in D:/Rebuttals/_registers/COPYRIGHT_REGISTER.json, effective 1 October 2010 to 15 March 2026, among them TX 8-396-625 (abstract, 2017), TX 8-648-723 (2018), TX 8-657-127 (buy text, 2018) and TX 9-504-677 (estimated, 2025). The 2026 package is protected from fixation (17 U.S.C. 102(a)); registration is the gateway to suit for U.S. works (17 U.S.C. 411(a)), and a certificate made within five years of first publication is prima facie evidence of validity (17 U.S.C. 410(c)).

Human authorship. Protection covers the human-authored expression and the author's selection, coordination and arrangement (U.S. Copyright Office registration guidance, March 2023). The protectable core here is human-authored: the concept, the numbered depositions written by Christopher Gabriel Brown, and his selection, arrangement and direction of this package. The README and CITATION.cff name him as inventor and author (D:/special/33-health-recovery/README.md; D:/special/33-health-recovery/CITATION.cff).

Notice practice. The notice sits in the LICENSE of both source folders and on the item page; it defeats an innocent-infringer defense (17 U.S.C. 401(d)).

7. Firm Rebuttals

Challenge 1 - "Vitamins, magnesium threonate and metal chelates are old. Nothing here is original."

Rebuttal. The owner claims combinations and methods, and the filed text says so. The NeuroElement application recites the seven-compound combination and its computational design method and distinguishes each named reference in paragraph [0009]; the filing checklist records that US 9,301,966 B2 "claims Mg-threonate ALONE for cognition" while this application claims it "as ONE OF SEVEN components" (Evidence 12). The coordination-complex library of 19/630,444 and the amino acid complexes of 19/441,975 and 19/445,644 stand on their own receipts (Evidence 6, 7, 9). A challenger must produce a dated record earlier than the matching filing date disclosing the same combination. None is of record.

Challenge 2 - "Someone filed first."

Rebuttal. Under first-inventor-to-file, the challenger must produce an application with an effective filing date earlier than 7 January 2026, 12 January 2026, 3 March 2026 or 27 March 2026, as the subject requires, claiming the same subject matter. None is of record. Any later filer meets the 2017 depositions and the dated listings as prior art under 35 U.S.C. 102(a)(1) (Evidence 3, 4, 5, 14).

Challenge 3 - "There is no issued patent, so there is nothing to respect."

Rebuttal. The owner holds five applications, filed and pending (Section 4). "Patent pending" marking is correct while an application is pending (35 U.S.C. 292). The bundle is also held by copyright, by the trade-secret measures of record and by its dated public record.

Challenge 4 - "It was published, so it is free to use."

Rebuttal. Publication is disclosure, not a grant. The LICENSE reads "NO LICENSE IS GRANTED." (Evidence 2); the item page states that intellectual property is not conveyed with purchase (Evidence 15); the purchase term grants the use of that blueprint only. The bundle listing of 6 June 2026 followed all five filings, so it is not prior art against them under 35 U.S.C. 102(a)(1); against every later filer it stands as dated prior art (Evidence 6 to 10, 14). Copyright continues after publication.

Challenge 5 - "AI made it, so there is no copyright."

Rebuttal. The protectable core is human-authored: the 2017 depositions written by Christopher Gabriel Brown (Evidence 3, 4, 5) and his selection, coordination and arrangement of seven research projects into this bundle. The March 2023 Copyright Office guidance protects exactly that. The 19/630,444 receipt lists his filed Oath or Declaration (Evidence 9).

Challenge 6 - "The dates can be faked."

Rebuttal. The dates rest on third-party records. ISBN 978-1-979767-89-7 identifies the CreateSpace edition first shipped 24 November 2017 (D:/manager/book-ocr-2017-invent-depositions/MANIFEST.md). Internet Archive first captures date crioner.com to 23 January 2010, cri-one.com to 28 January 2011 and buyinvent.com to 5 March 2014 (D:/manager/first-to-market/wayback_evidence.json). The USPTO prints a SHA-512 message digest for each filed document; the SHA-512 digests of the Project 13 folder's aia0001.pdf and sb0015a.pdf equal two digests printed on the 19/630,444 receipt character for character (Evidence 9). Stripe stamped the Payment Link 2026-10-08T04:56:07Z (D:/special/crione-static/delivery-v2/payment_links_ledger.live.json). This record's files are fingerprinted by SHA-256 in D:/Rebuttals/_evidence/8481.sha256.

Challenge 7 - "This bundle sells disease treatments."

Rebuttal. This is a research and discovery IP record and makes no treatment claim. The approved public wording states that the disease-mechanism research "consists of computational research findings that have not been clinically validated" and that "Nothing in this package constitutes medical advice." (Evidence 1). The item sold is the blueprint package; patent claims define the scope of the right sought at the USPTO and represent to no one that a composition works. The owner's regulatory memo keeps the halves apart: "The research half is licensed B2B as IP under NDA" (D:/special/45-fda-rebuttles-and-adwork/33-health-recovery/FDA_REBUTTAL.md).

Challenge 8 - "A discovery score of 50.5 out of 100 and a probability of 0.010094 are numbers pulled from the air."

Rebuttal. The owner's files define both figures, and the record holds them exactly. Each compound receives "a discovery score out of 100 based on its mechanism coverage, probability ranking, and transformation richness"; the top diabetes candidate, C-H-O-N, scored 50.5 / 100 with a probability of 0.010094 (Evidence 1). The methodology file records that discovery scores "reflect database coverage and mechanism overlap" and that probability values are "mathematical calculations from the Alchemy system" (Evidence 13). They are database-coverage figures, quoted exactly as recorded.

Challenge 9 - "It is just an idea in 3,571 files of compressed filler."

Rebuttal. The package is concrete work product: 128 Python files of 32,035 lines, among them the discovery engines and a pytest suite; 136 SVG drawings; nine formulation specifications and the discovery data in JSON; application texts for five research lines; and the USPTO receipts (Section 2; Evidence 6 to 9, 12). 2,605 of the archives sit in the Alchemy Probability Data folder, the engine the approved wording names "the shared analytical backbone" of the research projects (Evidence 1).

8. Evidence Index

#FileSHA-256 (first 16 hex)What it proves
1D:/special/_inventory/descriptions-public/8481.mda814d8c8b9daac38Approved public wording, contents, scores
2D:/special/33-health-recovery/LICENSEd1b5c2080f6f389bNotice, exclusive property, no license granted
3D:/special/82-alchemy-calc-two/1 light trigger.txt2dcb359de3f1b56dMaster IP register; #148, #201, #373, #769
4D:/manager/book-ocr-2017-invent-depositions/entries-index.csv9e72c4638df2ca6eDeposition #769 on printed page 181
5D:/manager/book-ocr-2017-invent-depositions/entries-clean.csvad3b87e885814dbb2017 catalog entries with copyright marks
6D:/USPTO Responses/Receipts/N417diabetes.pdfa2aa6ac673f1873f19/441,975 receipt (legacy file name)
7D:/USPTO Responses/Receipts/N417parkinsons.pdfbb5b87bad4927f6219/445,644 receipt
8D:/USPTO Responses/Receipts/N417 (14).pdfca48a9d5f3d7e7f819/555,525 receipt
9D:/USPTO Responses/Receipts/N417 (10).pdf2c8eededd0c15fa119/630,444 receipt and SHA-512 digests
10D:/USPTO Responses/EPSCAN/20160101_000000(35).PDFb858723d9abb8e1e19/693,405 Filing Receipt
11D:/manager/work/2 current_work_catalog.txt5b7a680d2563d031Project 33 in the as-filed umbrella catalog
12D:/special/33-health-recovery/22-brain-chemistry/patent_application/FILING_CHECKLIST_AND_IP_ANALYSIS.md486c1a33bf24da91Prior art named and distinguished
13D:/special/33-health-recovery/10-diabetes-cure-discovery/METHODOLOGY.md08abc89f652f8a58Definition of discovery scores
14D:/manager/export_catalog_product_20260617_063437.csveb42a3341d15c5e9Listing created 6 Jun 2026, online
15D:/special/crione-static/site-inventory/inventory/item-8481/index.html361b78352ff4af87Item page, no-IP-conveyed statement, notice

9. Notice Line

© 2017-2026 Christopher Gabriel Brown (CRI-ONE). All rights reserved. Patent pending - U.S. Application Nos. 19/441,975, 19/445,644, 19/555,525, 19/630,444 and 19/693,405.

This invention blueprint: Health Recovery · $2B.
cri-one.com/33-health-recovery.html
Also sold as part of Cri-One Health 2026 · $10.08B.
Payment is by bank transfer through Stripe.
Go to cart
Page 1 of 1
0% read